Brought to you by 
Daiichi and Rigel research new cancer strategy
14 Mar 2007
Executive Summary
Daiichi (Japanese pharma with strong cancer franchise) will support the work of Rigel Pharmaceuticals (functional genomics technology for drug discovery) in an emerging area of oncology therapeutics called protein degradation.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Daiichi and Rigel research new cancer strategy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice